吉西他滨联合顺铂治疗不同年龄晚期非小细胞肺癌的临床观察

Clinical observation of advanced non-small cell lung cancer patients with different age treated with gemcitabine plus cisplatin combined chemotherapy

目的:观察不同年龄晚期非小细胞肺癌(NSCLC)患者接受吉西他滨与顺铂联合化疗时,有效率及毒副反应的差异。方法:观察我院49例接受吉西他滨与顺铂联合化疗方案的NSCLC患者,根据年龄分为≥70岁组和<70岁组,对两组患者疗效进行比较。结果:49例患者均可进行临床评价,≥70岁组和<70岁组的临床有效率分别为42.9%和40.0%;毒副反应血小板减少、恶心呕吐、乏力发生率分别为21.4%、14.3%、14.3%和11.4%、5.7%、0。结论:一般情况较好的高龄(≥70)NSCLC患者可以接受吉西他滨与顺铂联合化疗方案。

Objective：To compare the elder（≥70） with younger（〈70） with advanced non-small cell cancer（NSCLC） patients treated with gemcitabine plus cisplatin in clinical efficacy and side effects.Methods：Total of 49 advanced NSCLC patients who had received gemcitabine plus cisplatin chemotherapy were retrospectively reviewed during 2004 to 2006.Results：All 49 patients had evaluable lesions.The response rate in elder group and younger group were 42.9% vs 40.0%.In elder group,the incidence of grade Ⅲ～Ⅳ thrombocytopenia,nausea and vomiting,inertia were 21.4%,14.3%,14.3%,respectively,in younger group,were 11.4%,5.7%,0%,respectively.Conclusion：Elder NSCLC patients are well tolerated to gemcitabine plus cisplatin chemotherapy.